Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Blood Coagulation Disorders

ClinicalTrials.gov lists 2,132 trials for Blood Coagulation Disorders or a narrower condition beneath it. Novo Nordisk A/S has the most among industry and government lead sponsors, with 84.

MeSH D001778 Hemic and Lymphatic Diseases C15
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 212 Phase 1/2 Phase 1/2 107 Phase 2 Phase 2 296 Phase 2/3 Phase 2/3 40 Phase 3 Phase 3 375 Phase 4 Phase 4 137 Not applicable Not applicable 271 Observational Observational 686 Phase 1 Phase 1 212 Phase 1/2 Phase 1/2 107 Phase 2 Phase 2 296 Phase 2/3 Phase 2/3 40 Phase 3 Phase 3 375 Phase 4 Phase 4 137 Not applicable Not applicable 271 Observational Observational 686

Trials per phase

2 more sections with rows

146 of the 2,132 trials are tagged with Blood Coagulation Disorders itself; the rest are tagged with a narrower condition beneath it.

Get the Blood Coagulation Disorders report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Blood Coagulation Disorders trials start? (36)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 8 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational
  • Other (Unknown)

Top of scale: 123

1990: 1 trials (Observational 1) 1992: 2 trials (Phase 2 1, Phase 1/2 1) 1993: 2 trials (Phase 2 1, Phase 1 1) 1994: 1 trials (Not applicable 1) 1995: 3 trials (Observational 3) 1996: 3 trials (Observational 1, Phase 2 2) 1997: 8 trials (Phase 4 1, Phase 3 2, Phase 2 1, Phase 1/2 1, Phase 1 3) 1998: 6 trials (Observational 1, Phase 3 1, Phase 2/3 1, Phase 1 3) 1999: 13 trials (Observational 3, Not applicable 2, Phase 3 2, Phase 2 2, Phase 1 4) 2000: 17 trials (Observational 2, Not applicable 4, Phase 4 1, Phase 3 4, Phase 2 4, Phase 1/2 1, Phase 1 1) 2001: 15 trials (Observational 1, Not applicable 1, Phase 4 2, Phase 3 5, Phase 2/3 2, Phase 2 3, Phase 1 1) 2002: 29 trials (Observational 7, Not applicable 2, Phase 3 6, Phase 2/3 1, Phase 2 6, Phase 1/2 4, Phase 1 3) 2003: 17 trials (Observational 2, Not applicable 2, Phase 4 4, Phase 3 2, Phase 2/3 2, Phase 2 3, Phase 1/2 1, Phase 1 1) 2004: 25 trials (Observational 8, Not applicable 1, Phase 3 6, Phase 2/3 1, Phase 2 6, Phase 1/2 1, Phase 1 2) 2005: 56 trials (Observational 13, Not applicable 5, Phase 4 3, Phase 3 13, Phase 2 11, Phase 1/2 3, Phase 1 8) 2006: 48 trials (Observational 8, Not applicable 6, Phase 4 7, Phase 3 9, Phase 2/3 2, Phase 2 11, Phase 1/2 1, Phase 1 4) 2007: 61 trials (Observational 18, Not applicable 4, Phase 4 2, Phase 3 11, Phase 2 15, Phase 1/2 5, Phase 1 6) 2008: 57 trials (Observational 12, Not applicable 3, Phase 4 5, Phase 3 10, Phase 2/3 3, Phase 2 12, Phase 1/2 5, Phase 1 7) 2009: 68 trials (Other 1, Observational 17, Not applicable 7, Phase 4 8, Phase 3 15, Phase 2/3 2, Phase 2 9, Phase 1/2 1, Phase 1 8) 2010: 74 trials (Observational 22, Not applicable 7, Phase 4 6, Phase 3 13, Phase 2/3 1, Phase 2 11, Phase 1/2 2, Phase 1 12) 2011: 71 trials (Observational 26, Not applicable 5, Phase 4 2, Phase 3 20, Phase 2/3 1, Phase 2 4, Phase 1/2 5, Phase 1 8) 2012: 81 trials (Observational 21, Not applicable 10, Phase 4 6, Phase 3 21, Phase 2/3 4, Phase 2 6, Phase 1 13) 2013: 54 trials (Observational 15, Not applicable 3, Phase 4 5, Phase 3 14, Phase 2/3 2, Phase 2 7, Phase 1/2 4, Phase 1 4) 2014: 89 trials (Observational 31, Not applicable 11, Phase 4 3, Phase 3 21, Phase 2/3 1, Phase 2 7, Phase 1/2 5, Phase 1 10) 2015: 107 trials (Observational 45, Not applicable 13, Phase 4 9, Phase 3 13, Phase 2/3 1, Phase 2 11, Phase 1/2 7, Phase 1 8) 2016: 76 trials (Observational 36, Not applicable 7, Phase 4 4, Phase 3 18, Phase 2/3 1, Phase 2 4, Phase 1/2 1, Phase 1 5) 2017: 96 trials (Observational 39, Not applicable 13, Phase 4 7, Phase 3 13, Phase 2/3 1, Phase 2 12, Phase 1/2 4, Phase 1 7) 2018: 101 trials (Observational 41, Not applicable 16, Phase 4 5, Phase 3 16, Phase 2 10, Phase 1/2 7, Phase 1 6) 2019: 99 trials (Observational 40, Not applicable 11, Phase 4 6, Phase 3 16, Phase 2/3 1, Phase 2 11, Phase 1/2 6, Phase 1 8) 2020: 119 trials (Observational 47, Not applicable 21, Phase 4 9, Phase 3 15, Phase 2/3 1, Phase 2 18, Phase 1/2 3, Phase 1 5) 2021: 123 trials (Observational 37, Not applicable 21, Phase 4 9, Phase 3 20, Phase 2/3 3, Phase 2 17, Phase 1/2 4, Phase 1 12) 2022: 109 trials (Observational 34, Not applicable 13, Phase 4 12, Phase 3 18, Phase 2/3 2, Phase 2 17, Phase 1/2 6, Phase 1 7) 2023: 111 trials (Observational 34, Not applicable 17, Phase 4 7, Phase 3 14, Phase 2/3 1, Phase 2 22, Phase 1/2 7, Phase 1 9) 2024: 121 trials (Observational 43, Not applicable 25, Phase 4 2, Phase 3 15, Phase 2/3 1, Phase 2 15, Phase 1/2 5, Phase 1 15) 2025: 122 trials (Observational 37, Not applicable 12, Phase 4 6, Phase 3 20, Phase 2/3 4, Phase 2 17, Phase 1/2 10, Phase 1 16)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 115
2025 122
2024 121
2023 111
2022 109
2021 123
2020 119
2019 99
2018 101
2017 96

Showing 10 of 36 earlier years.

Start your 14-day trial Email me all 36 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 130 trials starting in 2026 and about 130 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 190 trials still running at the 2026-10-09 snapshot; registered median of 26 months across 1,279 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Blood Coagulation Disorders trials in? (10)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 212
Phase 1/2 107
Phase 2 296
Phase 2/3 40
Phase 3 375
Phase 4 137
Not applicable 271
Observational 686
Expanded access 7
Unknown 1

How many Blood Coagulation Disorders trials are recruiting? (12)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 97
Recruiting 270
Enrolling by invitation 18
Active, not recruiting 86
Available 3

Showing 5 of 12 statuses.

Start your 14-day trial Email me all 12 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Blood Coagulation Disorders trials? (10)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
Novo Nordisk A/S 84
Baxalta now part of Shire 63
Bayer 61
Pfizer 46
CSL Behring 44

Showing 5 of 10 sponsors.

Start your 14-day trial Email me all 10 sponsors as a PDF

Which drugs are being tested for Blood Coagulation Disorders? (9)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Eltrombopag 52
ADVATE 38
RITUXIMAB 36
Romiplostim 31
Cytoxan 30

Showing 5 of 9 drugs.

Start your 14-day trial Email me all 9 drugs as a PDF

Interventions as named in the registry (6)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Dexamethasone/Dexamethasone acetate 41
SQ Fludarabine 29
Peripheral blood stem cell transplantation 25
Recombinant Factor VIII (50 IU/kg) 20
Cyclosporine 0.05% 20

Showing 5 of 6 interventions.

Start your 14-day trial Email me all 6 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Blood Coagulation Disorders trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Pneumonia 248 73
Thrombocytopenia 207 56
Factor VIII inhibition 150 18
Anaemia 132 46
Pyrexia 129 47

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Blood Coagulation Disorders? (486)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Prothrombin Complex Concentrate vs Frozen Plasma for Coagulopathic Bleeding in Cardiac Surgery: The FARES-II Multicenter Randomized Clinical Trial. JAMA 2025 Yes
Early clinical evaluation of a machine-learning system for risk prediction of trauma-induced coagulopathy in the prehospital setting. Emergency medicine journal : EMJ 2025 Yes
Current Practice Regarding Bleeding Disorders of Unknown Cause in the Netherlands: A National Survey. Haemophilia : the official journal of the World Federation of Hemophilia 2025 Yes
Hydroxychloroquine does not affect endotheliopathy or coagulopathy biomarkers in COVID-19: longitudinal results from the DisCoVeRy randomized trial. Angiogenesis 2025 Yes
The nature and timing of coagulation dysfunction in a cohort of trauma patients in the Australian pre-hospital setting. Injury 2024 Yes

Showing 5 of 486 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Sub-conditions in MeSH (10)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages